There is no specific date,but the company mentioned thru email reply (about 2 months ago) that they have an ability to release data before Feb.2016.btw.already Funded to P2 Localized prostate cancer.
Market cap is only $23m,check average cap of other P3 bios,it's several times higher.
"Analyst Doug Loe writes that not only was the study a positive data point, “but particularly so when considering the multiple Phase 3 failures experienced by Sophiris’ BPH drug development peers in recent years, making the achievement of generating a positive Phase 3 efficacy signal in this difficult-to-treat medical market even more compelling.”
The key takeaway is that “we have heightened confidence in PRX-302’s approvability in the difficult-to-treat BPH market,” he added.
Mr. Loe also said the long-term efficacy in the PLUS-1 study from only a single intra-prostatic injection at enrollment is hugely positive for PRX-302’s medical and commercial prospects."
From the report: "Our due diligence suggests that Sophiris has more than enough financial resources to fund operations with no additional share issuances through its next Phase III trial.
Given the substantial size of the benign prostatic hyperplasia (BPH or enlarged prostate) market, we estimate peak sales over $700 million. We believe the company will achieve a favorable outcome in its 2nd Phase III trial, which we expect to have a reduced trial completion time. As such, we are buyers of Sophiris."
that's why I'm buying SPHS,it's a joke MV and as far as i know very solid as well.
News 
Market Data 
Discover 
